Assertio Holdings (ASRT) closed out FY 2025 with Q4 revenue of US$13.5 million and basic EPS of a US$1.86 loss, alongside a trailing twelve month revenue base of US$118.7 million and basic EPS of a US$4.74 loss. Over the past year, quarterly revenue has moved between US$26.5 million and US$49.5 million, while quarterly basic EPS has ranged from a US$2.56 loss to US$1.78, leaving investors focused on how these shifts are feeding through to underlying margins.

See our full analysis for Assertio Holdings.

With the headline numbers set, the next step is to see how this earnings profile lines up with the widely held narratives around Assertio’s risks, rewards, and potential earnings recovery.

Losses Remain Heavy With US$30.4 Million TTM Net Loss

• Over the last twelve months, Assertio reported total revenue of US$118.7 million against a net loss of US$30.4 million and basic EPS of a US$4.74 loss, with quarterly net income swinging from an US$11.4 million profit in Q3 FY 2025 to an US$11.9 million loss in Q4.
• Bears highlight that losses have grown at about 21.8% per year over five years and see the current trailing loss profile as a red flag for future earnings durability.
  • The Q4 FY 2025 net loss of US$11.9 million, following a US$16.4 million loss in Q2 and US$13.5 million loss in Q1, reinforces concerns that positive Q3 profit has not yet translated into a consistent earnings pattern.
  • With trailing twelve month EPS at a US$4.74 loss and net loss at US$30.4 million, critics argue that the business still relies on a clear improvement in profitability to support any longer term earnings story.

Against this backdrop of swings between profit and loss, skeptics argue that one strong quarter is not enough to offset a multi year loss trend, especially when the latest quarter is back in the red. 🐻 Assertio Holdings Bear Case

Low 1.2x P/S Multiple Versus 5.2x Industry

• The stock trades on a P/S of 1.2x, compared with 5.2x for the broader US Pharmaceuticals industry and 4.4x for peers, meaning investors are currently paying a lower multiple of Assertio’s US$118.7 million trailing revenue than for many comparable companies.
• Bullish investors point to this low sales multiple alongside forecasts for earnings to grow 71.3% per year and turn profitable within three years as a potential mismatch between current pricing and future earnings power.
  • Consensus in the dataset points to earnings moving from a US$30.4 million loss today to US$11.2 million profit by around 2029, which supporters view as a sizeable swing against the present loss making base.
  • With a single analyst target level referenced at US$23.87 versus a current share price of US$22.37, backers see limited gap to that target on today’s price, and they still focus on the combination of low P/S and forecast earnings recovery as the core part of the optimistic case.

Optimists argue that if the company can move from a US$30.4 million loss to positive earnings while trading at a 1.2x P/S, that setup could justify a closer look at the more upbeat revenue and margin scenarios. 🐂 Assertio Holdings Bull Case

Revenue Growth Forecast At 0.3% Versus Market’s 11.4%

• Revenue is forecast to grow at 0.3% per year compared with a forecast 11.4% per year for the wider US market, even though trailing twelve month revenue sits at US$118.7 million and has recently ranged between US$117.1 million and US$137.4 million on a rolling basis.
• The balanced narrative flags this slow top line outlook as a key tension, because forecasts also assume margins improve from about a 25.6% loss today to 10.9% in three years, so much of the expected earnings improvement rests on better profitability rather than faster sales growth.
  • Analysts in the dataset expect earnings to move to roughly US$11.2 million by around 2029 on revenue of about US$102.9 million, which would imply higher margins even as revenue is expected to be lower than the current US$118.7 million trailing level.
  • This combination of modest revenue outlook and margin improvement means investors watching FY 2025 results may focus more on cost structure and product mix than on headline sales growth when judging how realistic the earnings path looks.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Assertio Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mixed views throughout this article, it makes sense to look at the full data set yourself and decide how comfortable you are with the trade off between current losses and the potential rewards investors are watching. To understand what is driving that optimism, take a closer look at the company’s 2 key rewards

See What Else Is Out There

Assertio’s heavy trailing losses, reliance on margin improvement over revenue growth, and forecast 0.3% revenue growth versus the market’s 11.4% highlight meaningful earnings and growth risks.

If that risk profile feels uncomfortable, shift your attention to 72 resilient stocks with low risk scores so you can quickly compare companies with steadier fundamentals and potentially sleep a little better about your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.